Showing results (1201-1210 of 1,832) with videos related to
Sort By:
Pageof 184
Signal Transduction and Targeted Therapy|September 1, 2024
Circulating tumor cells: from new biological insights to clinical practiceXuyu Gu, Shiyou Wei, Xin LvSignal Transduction and Targeted Therapy|August 22, 2024
Annexin A1 binds PDZ and LIM domain 7 to inhibit adipogenesis and prevent obesityLu Fang, Changjie Liu, Zong-Zhe Jiang, et al.Signal Transduction and Targeted Therapy|August 25, 2024
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal dataZifan Chen, Yang Chen, Yu Sun, et al.Signal Transduction and Targeted Therapy|August 22, 2024
Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategiesJifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.Signal Transduction and Targeted Therapy|November 26, 2024
Epigenetics-targeted drugs: current paradigms and future challengesWanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.Signal Transduction and Targeted Therapy|August 11, 2024
Current advance of nanotechnology in diagnosis and treatment for malignant tumorsBilan Wang, Shiqi Hu, Yan Teng, et al.Signal Transduction and Targeted Therapy|August 12, 2024
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trialHua-Qiang Zhou, Ya-Xiong Zhang, Gang Chen, et al.Signal Transduction and Targeted Therapy|August 11, 2024
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapiesYing-Chao Yuan, Hao Wang, Ze-Ju Jiang, et al.Signal Transduction and Targeted Therapy|July 16, 2024
Bacterial persisters: molecular mechanisms and therapeutic developmentHongxia Niu, Jiaying Gu, Ying ZhangSignal Transduction and Targeted Therapy|July 18, 2024
In vivo evaluation of guide-free Cas9-induced safety risks in a pig modelWeikai Ge, Shixue Gou, Xiaozhu Zhao, et al.Pageof 184